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After the International Investigative 
Dermatology (IID) meeting in Kyoto, 
Japan, the Post-IID International 
Meeting on Autoimmune Bullous 
Diseases was held (Figure 1).* 
Although many new findings had been 
presented at the IID meeting, addi-
tional discussion time was needed 
to explore selected topics in greater 
detail. At the Post-IID meeting, each 
speaker was allotted 10 minutes to 
present and 5 minutes to discuss, fol-
lowed by 30–40 minutes of com-
bined discussion for each session. 
Slides related to previous questions 
were shown again during the discus-
sion. The more than 140 experts who 
attended enjoyed considerable debate 
on various topics in autoimmune 
bullous disease; in fact, in all of the 
sessions, so many hands were raised 
that the moderators found it difficult 
to accommodate everyone who want-
ed to speak. Even in such a setting, it 
was not possible to address all points 
of view in this active and developing 
field. However, the meeting success-
fully established a common base from 
which to proceed with further investi-
gation into the pathophysiological and 
immunological mechanisms of auto-
immune bullous diseases.
Desmosome dynamics  
in health and disease
This session, moderated by Kathleen 
J. Green (Northwestern University, 
Chicago, IL), addressed recent break-
throughs in characterizing desmosomal 
components in normal and diseased 
conditions. Peter J. Koch (University 
of Colorado, Denver) reported on 
a conditional knockout mouse for 
desmocollin-3, specifically within 
stratified epithelia, using the Cre-
loxP system. Interestingly, these mice 
demonstrated intraepidermal blister 
formation with suprabasilar acantho-
lysis that was indistinguishable from 
that observed in pemphigus vulgaris. 
This study provided insight into the in 
vivo adhesive role of desmocollin-3 
in the epidermis. Green provided evi-
dence that the cytoplasmic domain of 
desmoglein 1 (Dsg1) has additional 
functions that regulate epidermal mor-
phogenesis. She reported differential 
effects of RNAi inhibition and chronic 
cleavage of Dsg1 by exfoliative toxin 
on organotypic raft culture. A co-
immunoprecipitation study revealed a 
complex composed of Dsg1 and cort-
actin, an Src-family kinase substrate, 
that governed actin dynamics during 
cell motility. Green proposed a novel, 
adhesion-independent role for Dsg1 in 
the localization and phosphorylation 
of cortactin, which may in turn facili-
tate the actin reorganization required 
for epidermal stratification and mor-
phogenesis.
Using fluorescence imaging, Andrew 
Kowalczyk (Emory University School of 
Medicine, Atlanta, GA) demonstrated 
that desmosome disassembly occurs 
in three phases in living kera tinocytes: 
Dsg3 endocytosis, disruption of desmo-
some organization, and loss of cell−cell 
adhesion strength. Dsg3 endocytosis 
occurs primarily from nondesmosomal 
pools, followed by a second phase of 
disassembly characterized by the rear-
rangement of Dsg3, desmoplakins, and 
other desmosomal components from the 
cell−cell inter face into the cytoplasm.
Autoantibody responses in pemphigus, 
pemphigoid, and epidermolysis bullosa 
acquisita
For 14 years, Luis A. Diaz (University 
of North Carolina, Chapel Hill) and 
his colleagues in Brazil have been sur-
veying the region of Limao Verde, one 
of the foci of Brazilian endemic pem-
phigus foliaceus, also known as “fogo 
selvagem.” They have found that in 
this area anti-Dsg1 autoantibodies are 
commonly detected, even in healthy 
individuals. IgM anti-Dsg1 autoanti-
bodies have also been detected and 
may prove to be a distinctive marker 
of fogo selvagem. It is interesting to 
note that these patients demonstrat-
ed a persistent IgM response, which 
typically occurs only transiently in 
early phases of an immune reaction. 
Using antibody phage display, Aimee 
S. Payne (University of Pennsylvania, 
Philadelphia) isolated anti-Dsg mono-
clonal antibodies from patients with 
pemphigus vulgaris and pemphigus 
foliaceus. Antibody gene sequence 
analysis indicated that a limited num-
ber of antibody variable-region genes 
had been used in the generation of 
pathogenic and nonpathogenic anti-
bodies. More interestingly, Payne and 
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John R. Stanley (also at the University of 
Pennsylvania, and the moderator of this 
session) reported that pathogenic mono-
clonal antibodies from humans and mice 
share a consensus motif (D/E-X-X-X-W) 
in the antigen-binding complementari-
ty-determining region 3 of heavy chains, 
which provides a valuable opportunity to 
target pathogenic pemphigus antibodies 
therapeutically.
John J. Zone (University of Utah, Salt 
Lake City) described an important role 
for IgE antibodies in the pathogenesis 
of bullous pemphigoid. IgE monoclo-
nal antibodies against LABD97, a por-
tion of the shed extracellular domain of 
BP180 (ColXVII), induced blisters with 
mast cell degranulation and eosino-
phil infiltration in human skin grafts. 
LABD97 from basement membrane 
zone degradation initiated IgE cross-
linking and mast cell degranulation with 
eosinophil infiltration and subsequent 
basement membrane zone vesiculation. 
Detlef Zillikens (University of Lübeck, 
Germany) presented two models of epi-
dermolysis bullosa acquisita: a passive 
transfer mouse model with rabbit anti-
type VII collagen (ColVII) antibodies and 
an active disease mouse model immu-
nized with a recombinant ColVII NC1 
domain. These models should be useful 
in analyzing autoimmune responses to 
ColVII and in developing more specific 
immunomodulatory therapies for 
epi dermolysis bullosa acquisita.
mysterious target antigens in 
autoimmune bullous diseases
Anti-p200 pemphigoid is a sub epidermal 
autoimmune bullous disease character-
ized by IgG antibodies directed against 
a prev iously unknown 200-kDa antigen. 
Using two-dimensional gel electro-
phoresis of dermal extracts and mass 
spectrometry, Teruki Dainichi (Kurume 
University School of Medicine, Japan) 
and his colleagues identified this anti-
gen as laminin-γ1. After sera were col-
lected from 20 patients with anti-p200 
pemphigoid, immunoblotting was used 
to demonstrate that 75−85% of the sam-
ples reacted with various affinity-purified 
laminins containing laminin-γ1. The 
major epitopes of laminin-γ1 resided 
in the C-terminal region. Immu no-
precipitation–immunoblotting assays with 
anti-laminin-γ1 monoclonal antibody 
and sera from anti-p200 pemphigoid 
patients confirmed the reactivity. This is 
a major advance in characterizing patho-
genic mechanisms of anti-p200 pemphi-
goid, as well as in addressing questions 
related to structural biology, particularly 
in terms of laminin−integrin interaction.
Sergei A. Grando (University of 
California at Irvine) discussed non-
desmoglein targets of pemphigus anti-
bodies, including acetylcholine receptors 
α3, α9, pemphaxin, the α-chain of the 
high-affinity IgE receptor, and neuronal 
voltage-gated K+ channels. The signifi-
cance of these nondesmoglein antibod-
ies was discussed intensively, including 
the fundamental question of whether 
they fulfill the immunological version of 
Koch’s postulates. A direct role for these 
antibodies in the pathogenesis of pem-
phigus remains uncertain.
The session was moderated by 
Takashi Hashimoto (Kurume University 
School of Medicine, Japan).
plenary lectures
The first of two plenary lectures was deliv-
ered by Mikio Furuse (Kobe University 
Graduate School of Medicine, Japan), 
who discussed the role of tight junctions 
in epithelial barrier function, with spe-
cial emphasis on the tight-junction-asso-
ciated membrane protein claudin. The 
heterogeneity in claudin content creates 
functional diversity in the barrier prop-
erties of tight junctions. Claudin 1–defi-
cient mice died within 1 day of birth 
with extremely dehydrated skin, indi-
cating that tight junctions in the stratum 
granulosum are crucial for maintaining 
barrier function in mammalian stratified 
squamous epithelia. The human claudin 
1 gene was identified as the causal gene 
for a syndrome associating ichthyosis and 
neonatal sclerosing cholangitis (NISCH 
syndrome). In the second plenary ses-
sion, Akihiro Kusumi (Institute of Frontier 
Medical Sciences, Kyoto University, 
Japan) described a novel technique of sin-
gle-molecule tracking in living cell mem-
branes. Application of this technique will 
broaden our understanding of molecular 
interactions in cell membranes.
Signal transduction: primary or 
secondary for acantholysis?
Signal transduction was one of the hot-
test topics discussed at the meeting. 
Yasuo Kitajima (Gifu University School of 
Medicine, Japan)—the session’s mod-
erator and a pioneer who in the early 
1990s proposed an important role for 
signal transduction in the process of 
acantholysis using cultured keratino-
cytes—sent out questionnaires to 
speakers and other attendees to deter-
mine a common basis for discussion. 
The participants were asked, for exam-
ple, whether antidesmoglein 3 (Dsg3) 
or Dsg1 antibodies are essential and 
specific in the pathogenesis of pemphi-
gus acantholysis (seven said yes, one 
said no) and whether the depletion of 
Dsg3 or Dsg1 is a specific characteris-
tic of keratinocytes in pemphigus (six 
“yes,” two “no”). David S. Rubenstein 
(University of North Carolina, Chapel 
Hill) demonstrated that MAPK p38 is 
activated by pemphigus IgG and that 
the blockade of p38 prevented blister 
formation in a passive transfer model 
using neonatal mice. Jens Waschke 
(Institute of Anatomy and Cell Biology, 
University of Würzburg, Germany), 
sharing data obtained via atomic force 
microscopy and laser tweezer experi-
ments, proposed that anti-Dsg3 IgG in 
pemphigus vulgaris may fulfill a differ-
ent role in the loss of cell–cell adhe-
sion than anti-Dsg1 IgG in pemphigus 
foliaceus. Eliane J. Müller (Institute of 
Animal Pathology, University of Bern, 
Switzerland) emphasized the impor-
tance of plakoglobin in acantholysis 
and its downstream effects on kera-
tinocyte proliferation and differen-
tiation. Yumi Aoyama (Gifu University 
School of Medicine, Japan) dem-
onstrated the involvement of p120-
catenin in pro-acantholytic signaling. 
The availability of pathogenic and 
nonpathogenic monoclonal antibod-
ies from pemphigus model mice (AK 
mAbs), as well as single-chain frag-
ment variants from patients (rather 
than serum-derived polyclonal IgG), 
has facilitated progress in this field 
and will continue to do so.
The possible involvement of apoptotic 
and cdk2 signaling was addressed by 
Carlo Pincelli (University of Modena, 
Italy) and Nicolla Cirillo (University of 
Naples, Italy), respectively. These sig-
naling theories were challenged by an 
argument that pemphigus acantholysis 
has not been regenerated using any 
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key signaling molecule without anti-
bodies against Dsg3 or Dsg1.
mouse model for pemphigus  
and pemphigoid
Three mouse models were discussed 
intensively in a session moderated by 
Masayuki Amagai (Keio University 
School of Medicine, Tokyo, Japan). 
The first was an active disease model 
for pemphigus generated by the adop-
tive transfer of Dsg3−/− lymphocytes 
into immunodeficient mice express-
ing Dsg3. This model was used to dis-
sect the immunological mechanisms 
of pathogenic anti-Dsg3 IgG produc-
tion and to characterize Dsg3-specific 
B and T cells. Hayato Takahashi (Keio 
University School of Medicine, Tokyo, 
Japan) reported that Dsg3-reactive T-cell 
clones show pathogenic heterogeneity 
in the induction of anti-Dsg3 IgG pro-
duction and that IL-4 plays an important 
role in this process. The second mouse 
model involved the humanized MHC 
class II and the CD4 coreceptor. These 
mice express the HLA class II alleles, 
DRB1*0402/DQB1*0302, which are 
strongly associated with pemphigus vul-
garis but lack endogenous mouse class 
II. Rüdiger Eming (Philipps University 
of Marburg, Germany) demonstrated 
that this model mimics, at least in part, 
immune responses to Dsg3 in patients 
and provides an excellent tool for study-
ing human responses in mice.
The final mouse model expressed the 
humanized bullous pemphigoid antigen, 
which was generated by the transgenic 
expression of human BP180 in BP180-
deficient mice, as presented by Wataru 
Nishie (Hokkaido University School of 
Medicine, Japan). This model overcame 
the long-standing problem of the lack 
of cross-reactivity between the human 
and mouse NC16a domains, the major 
epitopes of BP180. The advantages 
and limitations of these models were 
discussed extensively. Although mice 
and humans are different, these mod-
els provide valuable tools with which 
to clarify unsolved mysteries in auto-
immune diseases and develop novel 
therapeutic strategies.
rituximab and iVig
Rituximab and intravenous immuno-
globulin (IVIG) are recently introduced 
approaches to treating pemphigus, and 
their effectiveness has been document-
ed in various institutes. In this session, 
moderated by Kim B. Yancey (University 
of Texas Southwestern Medical Center, 
Dallas), speakers shared their clinical 
experiences using rituximab, in France 
(Pascal Joly, Rouen University Hospital), 
Germany (Enno Schmidt, University of 
Lübeck), and the United States (Jean-
Claude Bystryn, New York University). 
Although protocols for the use of ritux-
imab—alone or in combination with 
other medications—differed among 
these investigators, all agreed that ritux-
imab is an effective treatment modality 
against pemphigus, which shows resis-
tance to other therapeutic options. Joly 
emphasized that a single cycle of ritux-
imab is sufficient, although its use should 
be limited to the most severe cases to 
prevent potentially severe side effects.
Koji Hashimoto (Ehime University 
Graduate School of Medicine, Japan) 
presented results of a randomized 
double-blind multicenter clinical trial 
that examined the effectiveness of IVIG 
in steroid-resistant pemphigus. The 
first such clinical trial for pemphigus, 
it used a novel primary end point: time 
to escape from the protocol. This study 
concluded that a single cycle of IVIG at 
400 mg/kg/day for 5 consecutive days 
can be a safe and effective treatment for 
severe steroid-resistant pemphigus.
A disease activity scoring system  
for pemphigus
Luca Borradori (University Hospital, 
Geneva, Switzerland) moderated a 
session in which participants examined 
validated scoring systems for rating 
disease activity, which are essential 
in large, multicenter controlled tri-
als. Victoria P. Werth (University of 
Pennsylvania, Philadelphia) and Michael 
Hertl (Philipps University of Marburg, 
Germany) discussed the reliability and 
validity of the Pemphigus Disease Area 
Index (PDAI), which was developed by 
the International Pemphigus Committee, 
and the Autoimmune Bullous Skin 
Disorder Intensity Score (ABSIS), which 
was developed by Rüdiger Eming and 
his colleagues at Marburg. Werth, 
who presented the initial comparison 
between PDAI and ABSIS data collected 
by 10 experienced dermatologists from 
several countries, indicated that the 
PDAI is more reproducible and demon-
strates better correlation with the con-
sensus opinion of a patient’s condition. 
Further studies, including photovalida-
tion tests, are required to confirm these 
results. Hertl pointed out that results 
of the PDAI and the ABSIS should also 
be compared with patients’ cumulative 
required dose of steroid, immunosup-
pressive agents, and titer of antidesmog-
lein IgG autoantibodies.
*The Post-IID International Meeting 
on Autoimmune Bullous Diseases was 
held at the Otsu Prince Hotel, Otsu, 
Japan, 17−19 May 2008.
Figure 1. participants in the post-iiD 2008 international meeting on Autoimmune Bullous Diseases.
